NASDAQ:RANI Rani Therapeutics Q1 2025 Earnings Report $0.78 +0.02 (+2.25%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.78 0.00 (-0.18%) As of 06/18/2026 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Rani Therapeutics EPS ResultsActual EPS-$0.22Consensus EPS -$0.22Beat/MissMet ExpectationsOne Year Ago EPSN/ARani Therapeutics Revenue ResultsActual Revenue$0.20 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARani Therapeutics Announcement DetailsQuarterQ1 2025Date5/13/2025TimeBefore Market OpensConference Call DateTuesday, May 13, 2025Conference Call Time9:30AM ETUpcoming EarningsRani Therapeutics' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Rani Therapeutics Earnings HeadlinesRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 15, 2026 | americanbankingnews.comRani Therapeutics Shareholders Back Board and Auditor at MeetingMay 29, 2026 | tipranks.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free. | Behind the Markets (Ad)Rani Therapeutics Announces $20 Million Equity FinancingMay 27, 2026 | tipranks.comRani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq RulesMay 26, 2026 | globenewswire.comRani Therapeutics Faces Nasdaq Bid Price Noncompliance NoticeMay 17, 2026 | theglobeandmail.comSee More Rani Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rani Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rani Therapeutics and other key companies, straight to your email. Email Address About Rani TherapeuticsRani Therapeutics (NASDAQ:RANI) is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones. Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery. In addition to its insulin candidate, the company is exploring oral formulations of GLP-1 receptor agonists and other therapeutic proteins. Rani has secured investigational new drug (IND) approvals and completed initial safety and pharmacokinetic assessments in humans, positioning its RaniPill platform for broader application across multiple chronic disease areas. Headquartered in San Jose, California, Rani Therapeutics leverages collaborations with research institutions and industry partners to streamline development and manufacturing. While still in the clinical stages, the company is preparing for pivotal trials and regulatory interactions to support future commercialization. Rani’s management team combines expertise from pharmaceutical development, medical device engineering and regulatory affairs, underscoring its commitment to transforming biologic drug delivery and expanding patient access globally.View Rani Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Credo Technologies Accelerates AI—Its Stock Price Will FollowCarMax In Reverse? Why You Should Buy Now Before the Big Catalysts EmergeJabil Just Gave Investors a Stronger Reason to Buy the DipCan Trupanion Turn Pet Insurance Loyalty Into Real Earnings?Okta’s AI Moment May Be Bigger Than Investors RealizeDave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround PlanMicrosoft’s Xbox Problem Is Bigger Than a Console War Upcoming Earnings FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
